{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-025377","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2023-05-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.019258+00:00","generated_at":"2026-06-14T21:19:48.064924+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AVROBIO reports positive Phase 1/2 gene therapy data for cystinosis; all patients off oral cysteamine up to 36 months","bullets":["All six patients remain off oral cysteamine up to 36 months post gene therapy.","Durable reduction in leukocyte cystine levels; tissue crystals declined below baseline in first 4 patients.","Neurocognitive tests (Beery VMI) show improvement/stabilization up to 36 months, suggesting CNS impact.","No drug-related adverse events or serious adverse events reported to date.","Positive regulatory feedback from FDA and MHRA to align on registration-enabling trial path."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-025377","json":"https://secwatch.observer/filing/0001140361-23-025377.json","markdown":"https://secwatch.observer/filing/0001140361-23-025377.md","text":"https://secwatch.observer/filing/0001140361-23-025377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123025377/0001140361-23-025377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123025377/brhc20053135_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T21:19:48.064924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}